论文部分内容阅读
丁胺卡那霉素(A miKacin)是目前较好的合成氨基糖苷类抗菌素新品。自1972年问世以来,国外已广泛应用于临床。其特点是对氨基糖苷类耐药菌株,包括绿脓杆菌有较强的抗菌作用,抗菌活性不易受阴性杆菌产生的多种氨基糖苷灭活酶的影响,从而显示其优于其它氨基糖苷类抗菌素的特点。本品国内已于80年代初研制成功,经少数单位临床试用,表明与国外同类产品抗菌活性一致。已知氨基糖苷类对动物的肾脏有潜在的毒性,这方面国外已有不少文献报道,其
Amikacin (amikacin) is currently a good new synthetic aminoglycoside antibiotics. Since its publication in 1972, foreign countries have been widely used in clinical. It is characterized by its strong antibacterial activity against aminoglycoside-resistant strains, including Pseudomonas aeruginosa, and its antibacterial activity is not easily affected by various aminoglycoside-inactivating enzymes produced by negative bacilli and thus shows its superiority over other aminoglycoside antibiotics specialty. This product has been successfully developed in the early 80s, the clinical trial by a small number of units, indicating that the antibacterial activity with similar foreign products. It is known that aminoglycosides are potentially toxic to the kidneys of animals and many foreign literature have been reported in this area.